Pathological features and clinical results of eosinophilic and
non-eosinophilic CRSwNP
A total of 47.22% of patients were classified with eosinophilic CRSwNP
in our study. For general VAS score in eosinophilic CRSwNP patients, the
decrease in the rh-bFGF nasal-drop group was more obvious than that in
the control group at 2 weeks (P3=0.005), 1
month(P3=0.04),6 months(P3=0.001) and 1
year(P3=0.04,Figure5A-D). The decrease in general VAS
scores in the rh-bFGF nasal-spray group was more obvious than in the
control group. However, statistical difference was only found at 6
months between nasal-spray and control group(P2=0.004,Figure5C). For
non-eosinophilic CRSwNP patients, no significant difference was found
among the three group after ESS, except for nasal-drop group at
1year(FigureS3A-D).
For SNOT-22 scores in eosinophilic CRSwNP patients, the reduction in
rh-bFGF nasal experimental groups was greater than in control group.
However, no significant difference was found(Figure5E-H). For
non-eosinophilic CRSwNP patients, significant difference was only found
between nasal-drop and control group at 2 weeks
(P1=0.15,P3=0.04,FigureS3E). 1 month and
1 year after ESS, the SNOT-22 scores of nasal-spray was significant
lower than that of control group(P1=0.04,FigureS3F,H).
As for other postoperative time points, there was no significant
difference in SNOT-22 score among the three groups(FigureS3F-H).
For L-K score of eosinophilic CRSwNP patients, the reduction in the
rh-bFGF nasal-spray group was more obvious than that of the control
group at both 2 weeks (P1=0.02) and 1
month(P1=0.01,Figure5E,F). Moreover, a significant
difference was found between the control and rh-bFGF nasal-drop groups
at 1 month(P3=0.01), 6 months(P3=0.04)
and 1 year(P3=0.01), but no significant difference was
observed at 2 weeks(P3=0.43,Figure5E-H). However, for
non-eosinophilic CRSwNP patients, only L-K score of nasal-drop group was
significant lower than control group at 1 month(P3=0.04,
FigureS3I-L).